APOA1 and chronic myelogenous leukemia, BCR-ABL1 positive: The current study shows that CIGB-258 protected lipid-free apoA-I (Figure 2 and Figure 3) against CML toxicity from proteolytic degradation, while our previous paper showed that CIGB-258 protected only HDL, not lipid-free apoA-I.